Insider Transactions in Q2 2022 at Ab Cellera Biologics Inc. (ABCL)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2022
|
Thermopylae Holdings Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
9,173
+0.02%
|
$73,384
$8.05 P/Share
|
|
Jun 13
2022
|
Thermopylae Holdings Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
54,915
+0.1%
|
$439,320
$8.03 P/Share
|
|
Jun 06
2022
|
Thermopylae Holdings Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
64,545
+0.12%
|
$451,815
$7.5 P/Share
|
|
May 18
2022
|
Carl L. G. Hansen Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
56,125
+14.29%
|
$112,250
$2.7 P/Share
|
|
May 16
2022
|
Veronique Lecault Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
200,000
+10.15%
|
$1,200,000
$6.34 P/Share
|
|
May 13
2022
|
Thermopylae Holdings Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
300,000
+0.54%
|
$2,100,000
$7.26 P/Share
|
|
May 12
2022
|
Andrew Booth Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
85,000
+38.03%
|
$425,000
$5.79 P/Share
|
|
May 12
2022
|
Thermopylae Holdings Ltd. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,408,468
+2.49%
|
$8,450,808
$6.41 P/Share
|